Latest studies
Every paper our editors flag with a plain-language note and an evidence rating. Filter by evidence, species, or design to find what actually applies to you.
- Study · Melanotan IIWeak / none
Five primary melanomas in situ in a patient with recent tanning bed use, melanotan exposure, and anabolic hormone use.
This single case report describes multiple in-situ melanomas in a patient with several concurrent exposures, including melanotan, tanning beds, and anabolic hormones. With multiple confounding factors and a sample of one, it cannot attribute causation to any single agent. Relevant to the safety discussion around unregulated melanotan use, with appropriate caution about what a case report can show.
JAAD case reportsn=—HumanJul 1, 2026 - Study · Melanotan IIWeak / none
Unregulated Melanotan Use Promoted via Social Media: Emerging Dermatologic and Public Health Risks.
This short commentary raises concern about social-media promotion of unregulated melanotan and the associated dermatologic and public-health risks. It is opinion and awareness-oriented rather than a data study, but it is directly on-topic for the melanotan safety and access narrative. Useful context for the risks of the unregulated market.
International journal of dermatologyn=——Jun 1, 2026 - Study · Melanotan IIWeak / none
Depigmented Facial and Neck Patches Following Melanotan Use in a Patient With Atopic Dermatitis and Alopecia Areata.
This single case report documents an unusual depigmentation pattern after melanotan use in a patient with pre-existing autoimmune skin conditions. The co-occurring diagnoses complicate attribution, and a case report cannot establish causation. Relevant to the catalog of reported adverse effects from unregulated melanotan use.
Clinical and experimental dermatologyn=—HumanMay 29, 2026 - Study · Melanotan IIWeak / none
Changes in Oral Mucosa Associated with Melanotan II Injections: A Case Report.
This single case report documents oral mucosal pigmentation appearing after self-administered Melanotan II and largely resolving after discontinuation. As a report of one patient it cannot establish frequency or causation, but it adds to the limited literature on melanotan-associated pigmentation and the risks of unregulated use. Useful detail for the melanotan safety picture.
Life (Basel, Switzerland)n=—HumanFeb 3, 2026 - Study · Melanotan IIWeak / none
Insights into Tanning Biology and Tanning Products.
This PRISMA-guided review of 68 studies covers several tanning agents, with melanotan among the dominant ones discussed. It catalogs serious adverse effects associated with unregulated melanotan use and notes limited long-term safety data across the literature. A useful safety-oriented reference for the melanotan risk profile.
The Journal of clinical and aesthetic dermatologyn=——Feb 1, 2026 - Study · Melanotan IIWeak / none
Pyoderma Gangrenosum Secondary to Melanotan.
This is the first reported case linking melanotan use to pyoderma gangrenosum, an ulcerating neutrophilic dermatosis, at the injection sites. As a single case report it is low on the evidence hierarchy and cannot establish causation, but it is directly about melanotan and adds to the documented safety signals for unregulated injectable use. Reported as an adverse event, not a proven effect.
Cureusn=—HumanDec 1, 2025 - Study · Melanotan IIWeak / none
Melanotan II nasal spray: a possible risk factor for oral mucosal malignant melanoma?
This single case report raises a possible association between Melanotan II nasal spray use and oral mucosal malignant melanoma in a young woman. As an isolated case it cannot establish causation, and the authors frame it as a question warranting awareness rather than a proven link. It is directly about the peptide and adds to documented safety concerns around unregulated use.
International journal of oral and maxillofacial surgeryn=—HumanSep 1, 2025 - Study · Melanotan IIWeak / none
A single-centre, prospective, qualitative analysis of knowledge, attitudes and behaviour of sunbed use among patients attending a pigmented lesion clinic.
This qualitative survey of sunbed users documents concurrent use of unregulated Melanotan I and II among tanning-focused patients and flags associated public-health risks such as blood-borne infection from injectable use. The peptides are examined as part of tanning behavior rather than for physiological effect. It offers useful real-world context on unregulated melanotan use.
Skin health and diseasen=——Jun 1, 2025 - Study · Melanotan IIWeak / none
Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II on male rats in a model of chronic unpredictable stress.
In a chronic-unpredictable-stress rat model of depression, low-dose Semax and Melanotan II were associated with reduced or attenuated stress-induced anhedonia (loss of sucrose preference), less suppression of body-weight gain, reduced adrenal hypertrophy and preserved hippocampal BDNF, though neither peptide changed immobility in the forced-swim test. This is a preclinical behavioral-pharmacology study in male rats only; the mixed endpoint results (positive on anhedonia, null on forced swim) argue for cautious interpretation. It adds a stress and mood strand to Semax's rodent literature and offers a plausible BDNF-linked mechanism, but says nothing about human mood outcomes. These are preclinical findings; human data are needed before clinical conclusions can be drawn.
European journal of pharmacologyn=—AnimalDec 5, 2024